Skip to main content

Advertisement

SpringerLink
Log in

Polatuzumab vedotin pharmacokinetics in a hemodialysis patient with diffuse large B-cell lymphoma

  • Short Communication
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Chemotherapy for the hemodialysis (HD) patient is a challenging situation because it requires special considerations including dose modifications and timing of drug administration in relation with HD sessions. Polaltuzumab vedotin (PV), an antibody–drug conjugate in which monomethyl auristatin E (MMAE) is linked to an anti-CD79b monoclonal antibody, is an extremely promising therapeutic for treating diffuse large B cell lymphoma (DLBCL), but the pharmacokinetics are unknown in HD patients.

Methods

We carried out pharmacokinetic studies of PV when administered at 1.2 mg/kg to a DLBCL patient on HD, and compared the results with that of non-HD patients. PV was administered in conjunction with bendamustine and rituximab.

Results

Serum concentration–time curves of both antibodyconjugated and unconjugated MMAE in the presented HD patient were similar compared to that of non-HD patients. We also demonstrate that elimination of both antibody-conjugated and unconjugated MMAE through HD is limited. PV administration at 1.2 mg/kg to an HD patient was also clinically feasible, and no signs of peripheral neuropathy were observed.

Conclusions

PV therapy may be a relatively safe treatment method for DLBCL patients on HD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Data availability

Data supporting this study’s findings are available from the corresponding author upon request.

References

  1. Hortlund M, Arroyo Muhr LS, Storm H et al (2017) Cancer risks after solid organ transplantation and after long-term dialysis. Int J Cancer 140(5):1091–1101

    Article  CAS  PubMed  Google Scholar 

  2. Yasuda H, Yasuda M, Komatsu N (2021) Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: a comprehensive review. Cancer Sci 112(7):2607–2624

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Zhao B, Chen R, O’Connor OA et al (2016) Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment. Br J Clin Pharmacol 82(3):696–705

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Nanni L, Pellegrini C, Stefoni V et al (2019) Successful employment of brentuximab vedotin in a patient undergoing hemodialysis: the first real-life experience. Clin Lymphoma Myeloma Leuk 19(11):e595–e596

    Article  PubMed  Google Scholar 

  5. Kinoshita T, Hatake K, Yamamoto K et al (2021) Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study. Jpn J Clin Oncol 51(1):70–77

    Article  PubMed  Google Scholar 

  6. Park MH, Lee BI, Byeon JJ et al (2019) Pharmacokinetic and metabolism studies of monomethyl Auristatin F via liquid chromatography-quadrupole-time-of-flight mass spectrometry. Molecules 24(15):2754

    Article  PubMed  PubMed Central  Google Scholar 

  7. Chang HP, Cheung YK, Shah DK (2021) Whole-body pharmacokinetics and physiologically based pharmacokinetic Model for Monomethyl Auristatin E (MMAE). J Clin Med 10(6):1332

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Yasuda H, Komatsu N, Ando J, Ando M (2022) Hodgkin lymphoma on hemodialysis: a review of treatment and recommendations. Clin Lymphoma Myeloma Leuk 22(11):805–811

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This study received no external funding.

Author information

Authors and Affiliations

  1. Department of Hematology, Juntendo University School of Medicine, 2-1-1 Hongou, Bunkyo-Ku, Tokyo, 113-8421, Japan

    Hajime Yasuda, Tomonori Ochiai, Tomohito Yamana, Midori Ishii, Makoto Sasaki, Jun Ando & Miki Ando

  2. Laboratory of Proteomics and Biomolecular Science, Biomedical Research Core Facilities, Juntendo University Graduate School of Medicine, Bunkyo-Ku, Tokyo, Japan

    Naoko Kaga, Hikari Taka & Yoshiki Miura

  3. Department of Orthopedic Surgery, Juntendo University School of Medicine, Bunkyo-Ku, Tokyo, Japan

    Midori Ishii

  4. Department of Cell Therapy and Transfusion Medicine, Juntendo University School of Medicine, Bunkyo-Ku, Tokyo, Japan

    Jun Ando

Authors
  1. Hajime Yasuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naoko Kaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hikari Taka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tomonori Ochiai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tomohito Yamana
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshiki Miura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Midori Ishii
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Makoto Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jun Ando
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Miki Ando
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

HY and MY wrote the manuscript. HT, NK, and MY measured antibody-conjugated and unconjugated MMAE serum concentration levels. TO, TY, MI, and MS collected and analyzed the data, and JA and MA revised the manuscript.

Corresponding author

Correspondence to Hajime Yasuda.

Ethics declarations

Conflict of interest

The authors have stated that they have no conflicts of interest.

Ethical approval

This study was conducted in accordance with the Declaration of Helsinki, was approved by the institutional ethics committee of Juntendo University School of Medicine (IRB#E22-0327), and written informed consent was obtained from the patient for publication of this report.

Consent for publication

Written informed consent was obtained from the patient for publication of this report.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yasuda, H., Kaga, N., Taka, H. et al. Polatuzumab vedotin pharmacokinetics in a hemodialysis patient with diffuse large B-cell lymphoma. Cancer Chemother Pharmacol 93, 265–268 (2024). https://doi.org/10.1007/s00280-023-04593-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-023-04593-w

Keywords

Search

Navigation